Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline.
Ardia will advance DIA-615, a clinic-ready topical candidate being developed for inflammatory skin diseases including psoriasis.
Bryan Jones has been appointed Chief Executive Officer of Ardia and will transition from his role as Aardvark's Chief Operating Officer. Jones brings more than 30 years of biotechnology and specialty pharmaceutical experience.
The move supports Aardvark's expansion beyond its metabolic disease programs, including the Phase 3 candidate ARD-101 for Prader-Willi syndrome and ARD-201 in Phase 2 development.
AARD closed Wednesday's trading at $12.67, up $0.06 or 0.48 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.